US index futures are trading lower during Tuesday’s session, with S&P 500 futures (US500) down nearly 0.7% and Nasdaq 100 futures (US100) losing almost 1.1%. Both benchmarks are heading for a third consecutive losing session. Uncertainty surrounding the Middle East remains elevated, while investors appear to be taking profits ahead of tomorrow’s quarterly earnings report from the world’s largest company, Nvidia (NVDA.US). The semiconductor sector is under particularly strong pressure.
Key developments
- According to Bloomberg reports, NATO is considering a potential military operation in the Strait of Hormuz if the key trade route is not reopened by July.
- The yield on 30-year US Treasuries climbed above 5.18%, reaching its highest level in nearly 19 years. Higher yields may increase mortgage and credit card borrowing costs, potentially weighing on consumer spending, while also adding pressure to highly valued technology and semiconductor stocks.
- Recent US data suggests inflationary pressures may be picking up again, partly due to higher oil prices following escalating tensions around Iran. Ed Yardeni believes the Fed may be “behind the curve” on inflation. In his view, a July rate hike could help contain inflation but would likely pressure equities.
- The US Pending Home Sales Index rose to 74.8 from 73.7 previously, signaling a modest improvement in housing market activity.
- Pending home sales increased 1.4% MoM, above expectations of 1.0%, although slightly below the prior reading of 1.5%. The data may be viewed positively for the US economy, suggesting continued resilience in the housing market despite elevated financing costs.
US500 chart (H1 interval)
The S&P 500 futures contract is lower today, but investor attention is focused primarily on semiconductor stocks. The Philadelphia Semiconductor Index is down 1.4% and has already retreated more than 8% over the past three sessions. Investors are taking profits after a strong rally, amid concerns about stretched valuations and the sustainability of data center spending.
Source: xStation5
As shown above, investors are clearly rotating out of semiconductor, electronics, and AI infrastructure stocks today. Software companies — a sector that has significantly underperformed since the start of the year - as well as consumer staples are outperforming. Big Tech stocks are broadly weaker, with Amazon shares down nearly 3%, while Alphabet (Google), Tesla, and Nvidia are also under pressure. Nvidia shares are once again struggling ahead of earnings.
Source: xStation5
Company news
Microsoft (MSFT.US) shares are not posting gains today despite the company unveiling new Surface devices aimed at business clients and AI acceleration applications. The new models are powered by Intel processors, representing another positive signal for Intel. However, Microsoft shares have already rallied more than 20% from their April lows.
Source: xStation5
Jazz Pharma shares extend gains
UBS upgraded Jazz Pharmaceuticals to “buy” from “neutral” and raised its price target to USD 307, implying more than 33% upside from Monday’s close. The bank points to the company’s resilient business model and the commercial potential of its oncology portfolio. Is Ziihera the key growth driver?
- UBS sees Ziihera, a treatment for gallbladder cancer, as the company’s main growth engine.
- The bank expects rapid adoption of the drug and a potential regulatory approval before the mandatory August 25 deadline.
- According to UBS, Ziihera could become a significant new revenue driver for the company.
UBS also remains positive on the stability of Jazz’s Sleep franchise, including Xywav and Xyrem. Pricing pressure and potential competition from Orexin-based therapies in the second half of 2026 are viewed as manageable risks. In the analyst’s view, these risks are outweighed by the growth opportunity represented by Ziihera.
The bank also highlighted Modeyso, a treatment targeting a specific type of brain cancer, which could generate meaningful sales over the next 1–2 years. Altogether, this supports the view that Jazz’s oncology pipeline may gradually become a more important contributor to the company’s financial results.
Jazz Pharmaceuticals (D1 interval)
Jazz Pharmaceuticals shares have gained almost 38% in 2026, while the stock price has doubled over the past 12 months. Despite the strong rally, analysts still see room for further upside, mainly driven by the potential of the company’s new therapies.
Source: xStation5
Will semiconductors enter the correction after the historic climb?
Nvidia earnings preview: Will it save market gains?
Will the CPU become the new Holy Grail of artificial intelligence?
Do Home Depot's results reflect the strength of the American consumer❓🛒
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
